CagriSema: the GLP-1 + amylin combo, and what its data really show

CagriSema is the drug that made a pharmaceutical company’s stock fall 20% in a day — not by failing, but by succeeding a little less than investors hoped. That story tells you almost everything about how to read it: the underlying trial data are substantial, and the headlines are a poor guide to them. This page separates the two.

One fact sits under everything else: as of mid-2026, CagriSema is investigational. It is not approved by the FDA, the EMA, or the MHRA. Novo Nordisk filed a US application for chronic weight management in December 2025, and the review is expected to play out during 2026. There is no approved CagriSema product, no approved label, and no pharmacy that can legally dispense it — because no such approved product exists yet.

What it actually is

After GLP-1, the next gut–brain hormone getting the spotlight is amylin. If GLP-1 is the “you’re full” message your body sends after a meal, amylin is a closely related message sent at the same time, from the same place — the pancreas. It slows stomach emptying, tells the body to ease off on glucagon, and acts on the brainstem to make you feel satisfied with less food.

CagriSema is a fixed-dose, once-weekly injectable that combines cagrilintide (a long-acting amylin analog) with semaglutide (the GLP-1 in Wegovy and Ozempic). The bet is simple to state: GLP-1 and amylin curb appetite through partly different routes, so hitting both at once might beat either alone. This is a real, mechanistically distinct idea — not a wellness-blog remix of Ozempic. The proof that amylin can be drugged in humans already exists: pramlintide, an older amylin analog, has been FDA-approved since the mid-2000s as a mealtime-insulin add-on in diabetes — real, approved, and deliberately modest.

What the strong evidence shows

The big phase-3 readouts are published in the New England Journal of Medicine.

REDEFINE 1 randomized 3,417 adults with obesity (or overweight with a complication) but without type 2 diabetes, over 68 weeks. Here an asterisk matters, because modern trials report results two ways. Under the treatment-policy estimand — which counts everyone regardless of whether they stuck with the drug, closer to real-world use — CagriSema produced about 20.4% mean weight loss versus ~3% on placebo. Under the trial-product estimand — the effect if everyone took it exactly as intended — the figure rises to about 22.7%. Both are real; the higher one simply assumes perfect adherence. Roughly 6 in 10 participants lost at least 20% of their body weight.

REDEFINE 2 studied 1,206 adults with overweight/obesity and type 2 diabetes. Weight loss was smaller — about 13.7% versus 3.4% on placebo — which is expected, since people with diabetes typically lose less on these drugs. But glucose control improved sharply: about 73% reached an HbA1c of 6.5% or lower, versus ~16% on placebo. (One caveat for readers with diabetes: strong glucose-lowering can raise the risk of hypoglycemia — low blood sugar — when a drug like this is combined with insulin or sulfonylureas, which is why those doses are usually adjusted under a clinician’s supervision.) The separate REIMAGINE program, peer-reviewed and presented at ADA 2026, found CagriSema met a superiority endpoint over semaglutide 2.4 mg alone on blood sugar (and showed greater weight loss) in type 2 diabetes — evidence that adding amylin does more than semaglutide by itself.

So the honest summary: in these trials the combination produced large weight loss — among the biggest reported for an injectable — though it remains investigational, and the long-term, comparative, and regulatory picture is still unsettled. That’s why the grade stays at emerging (“promising but unproven”).

The head-to-head reality check

The most important nuance is the one the marketing won’t lead with. In the open-label REDEFINE 4 trial (against tirzepatide 15 mg, the highest approved dose), CagriSema did not meet its primary endpoint of non-inferiority. It produced about 23.0% weight loss versus 25.5% for tirzepatide under the “if everyone adhered” estimand (20.2% vs 23.6% under the real-world estimand). In plain terms: both drugs drove large weight loss, but CagriSema came in numerically behind tirzepatide and could not statistically prove it was “no worse.” (The trial was open-label, which can bias an unblinded weight comparison — but the direction is clear.) As of mid-2026 this is a company topline, not yet peer-reviewed. The takeaway: CagriSema looks like a powerful candidate, but — even setting aside that it isn’t approved or available — the claim that it’s the single most effective drug in the class is not supported by the head-to-head data.

Safety, in brief

The safety story is largely the familiar GLP-1/amylin gastrointestinal one. In REDEFINE 1, adverse events were predominantly GI — nausea, constipation, and vomiting, more common than on placebo — mostly mild to moderate and typically managed by starting at a low dose and increasing gradually, with a low (single-digit) discontinuation rate.

Some symptoms, though, are not part of the expected settling-in and warrant prompt medical attention rather than waiting them out: severe or persistent abdominal pain (which can radiate to the back), repeated vomiting with signs of dehydration, or yellowing of the skin or eyes — these can signal pancreatitis or gallbladder problems seen with GLP-1 drugs.

Because CagriSema contains semaglutide, the GLP-1 class cautions carry over (detailed on our semaglutide side-effects page): a boxed thyroid warning — semaglutide should not be used by people with a personal or family history of medullary thyroid cancer or MEN2 — plus pancreatitis and gallbladder cautions. Two points matter for the people most likely to read this: like other GLP-1 medicines, this class is not recommended in pregnancy, and clinicians generally advise stopping well before trying to conceive (see GLP-1s & birth control); and, as with any rapid weight loss, some of the weight lost is lean muscle — which is why protein intake and resistance activity are worth raising with your clinician.

As an investigational product, its long-term safety record in the general population simply does not exist yet — a real limitation, not a reassurance.

Where it outruns the data

“Cagrilintide” is now sold by grey-market peptide vendors as a standalone weight-loss compound, often citing these very trial numbers. Those numbers come from a pharmaceutical-grade product in monitored trials — not from a research-chemical vial of uncertain identity, purity, or sterility — meaning real risks of injecting the wrong dose, a contaminated product, or an unsterile injection — and the combination’s results in particular cannot be assumed for cagrilintide taken alone. The FDA has warned about unapproved GLP-1 products; the same logic applies here. There is no approved cagrilintide or CagriSema to buy at a pharmacy, and what’s sold outside a trial is a different question from the one the trials answered.

What we still don’t know

The open questions are real: whether the FDA approves it and on what label; how it performs on cardiovascular outcomes (no dedicated outcomes trial has reported); whether adding amylin improves weight maintenance or reduces regain after stopping, compared with GLP-1 alone; and its long-term durability and safety. Until those read out — and until there’s an approved product — CagriSema is a genuinely promising drug to watch, not a decision you can act on today. That conversation belongs with a clinician, against your own history.